In Switzerland, both the currently approved monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and the Janus kinase (JAK) inhibitors (baricitinib, abro-citinib, upadacitinib) can be used as “first-line” systemic therapy for patients with atopic dermatitis after an inadequate response to topical treatment. The choice is therefore large – making the question of subjective and objective decision criteria all the more important.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Prurigo nodularis
Retrospective analyses of large data sets from everyday practice
- Public Health
Outpatient care in Switzerland: situation report
- Practice Management
Improved quality of care aims for satisfied patients
- Chemsex - MSM, sex, chrystal meth & co.
Medical and psychosocial perspectives
- Bladder cancer
Tuberculosis vaccination reduces recurrences
- Oral JAK-i in atopic dermatitis
Benefits and risks: What does the current data say?
- Chronic lung diseases
Sarcopenia and malnutrition in the context of pneumological rehabilitation
- Sleep-wake disorders in pneumology practice